Abstract: The present invention relates to compositions comprising one or more anthraquinones for use in the treatment of obesity and related metabolic and liver disease. More particularly it relates to a plant extract fraction rich in anthraquinones including both anthraquinone glycosides and anthraquinone aglycones obtainable from a member of the Leguminosae family, more particularly Cassia seeds. It also relates to a method of obtaining a plant extract fraction rich in anthraquinones.

Abstract: The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterized product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb Astragalus extract, or an active fraction thereof, for use as an antiviral in the treatment of hepatitis C.

Abstract: The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterised product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb Astragalus extract, or an active fraction thereof, for use as an antiviral in the treatment of hepatitis C.

Abstract: The present invention relates to a botanical drug or dietary supplement for use in the treatment of patients suffering from Hepatitis C virus infection. More particularly, it relates to a botanical drug consisting essentially of four botanical drug substances, optionally formulated with excipients, for use either in alleviating the symptoms of Hepatitis, particularly chronic Hepatitis C, and/or inhibiting the activity of the causative Hepatitis C virus. The botanical raw materials, botanical drug substances or botanical ingredients used are from a species of each of the genera: (a) Silybum; (b) Astragalus or Hedysarum; (c) Salvia; and (d) Schisandra.